Relay Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Relay Therapeutics
RLAY Stock  USD 8.18  0.28  3.31%   
Relay Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Relay Therapeutics' valuation are provided below:
Gross Profit
-259.2 M
Market Capitalization
1.4 B
Enterprise Value Revenue
102.295
Revenue
8.4 M
Earnings Share
(1.72)
We have found one hundred twenty available trending fundamental ratios for Relay Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Relay Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 503.3 M in 2026. Enterprise Value is likely to drop to about 438.5 M in 2026

Relay Therapeutics Total Revenue

14.01 Million

Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 42 M, Interest Income of 42 M or Depreciation And Amortization of 4.3 M, as well as many indicators such as Price To Sales Ratio of 64.26, Dividend Yield of 0.0 or PTB Ratio of 1.24. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Relay Stock
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Relay Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets855.6 M1 B631.3 M
Slightly volatile
Short and Long Term Debt Total36.5 M55.8 M19.2 M
Slightly volatile
Other Current Liabilities15.5 M26.7 M9.2 M
Slightly volatile
Total Current Liabilities31.7 M58.3 M20.4 M
Slightly volatile
Other Liabilities21.6 M37.2 M13.3 M
Slightly volatile
Property Plant And Equipment Net46.1 M66.3 M25.6 M
Slightly volatile
Current Deferred Revenue6.2 M8.8 M4.6 M
Slightly volatile
Accounts Payable9.5 M16.2 M7.3 M
Slightly volatile
Cash106.3 M111.9 M355.8 M
Slightly volatile
Non Current Assets Total49.5 M71.4 M27.8 M
Slightly volatile
Non Currrent Assets Other2 M2.4 M1.4 M
Slightly volatile
Other Assets1.5 M3 M1.4 M
Slightly volatile
Cash And Short Term Investments776.9 M898.5 M587.7 M
Slightly volatile
Common Stock Total Equity71.9 K139.2 K47.3 K
Slightly volatile
Common Stock Shares Outstanding89.5 M164.3 M49.6 M
Slightly volatile
Liabilities And Stockholders Equity855.6 M1 B631.3 M
Slightly volatile
Non Current Liabilities Total36.6 M38.5 M337.1 M
Slightly volatile
Capital Surpluse2.4 B2.3 B805.3 M
Slightly volatile
Capital Lease Obligations36.5 M55.8 M19.2 M
Slightly volatile
Other Current Assets33.7 M32.1 M8.9 M
Slightly volatile
Other Stockholder Equity1.5 B2.9 B823.3 M
Slightly volatile
Total Liabilities79.9 M84.2 M357.4 M
Slightly volatile
Property Plant And Equipment Gross59.5 M99.6 M33.3 M
Slightly volatile
Total Current Assets806.1 M930.6 M603.5 M
Slightly volatile
Capital Stock97.7 K193.2 K55.1 K
Slightly volatile
Non Current Liabilities Other28.5 M15.2 M12.8 M
Slightly volatile
Net Working Capital774.4 M872.2 M583.1 M
Slightly volatile
Short Term Debt6.9 M6.6 M2 M
Slightly volatile
Common Stock97.7 K193.2 K55.1 K
Slightly volatile
Property Plant Equipment13.2 M10.5 M9.3 M
Slightly volatile
Intangible Assets1.8 M2.1 M2.3 M
Slightly volatile

Relay Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income42 M40 M10.6 M
Slightly volatile
Interest Income42 M40 M10.6 M
Slightly volatile
Depreciation And Amortization4.3 M6.3 M3.2 M
Slightly volatile
Selling General Administrative52.8 M88.1 M32.2 M
Slightly volatile
Other Operating Expenses270.6 M439.8 M166.5 M
Slightly volatile
Research Development201 M367 M128 M
Slightly volatile
Cost Of Revenue4.3 M6.3 M3.2 M
Slightly volatile
Total Operating Expenses270 M439.8 M166.3 M
Slightly volatile
Reconciled Depreciation4.3 M6.3 M3.2 M
Slightly volatile
Total Other Income Expense Net42 M40 M10.6 M
Slightly volatile
Non Operating Income Net Other10.6 M10.1 M4.8 M
Slightly volatile
Non Recurring98.4 M110.7 M120.8 M
Slightly volatile
Selling And Marketing Expenses3.4 M3.8 M4.2 M
Slightly volatile

Relay Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation113.7 M108.3 M33.5 M
Slightly volatile
Begin Period Cash Flow179.5 M131.8 M145.2 M
Slightly volatile
Other Cashflows From Financing Activities3.6 M3.8 M211.1 M
Slightly volatile
Depreciation4.3 M6.3 M3.2 M
Slightly volatile
Capital Expenditures2.2 M2.3 M2.8 M
Slightly volatile
Issuance Of Capital Stock202.2 M239.3 M315.6 M
Slightly volatile
Total Cash From Financing Activities206.9 M243.1 M318.8 M
Slightly volatile
End Period Cash Flow185.6 M113.8 M311.9 M
Slightly volatile
Change To Netincome67.8 M64.6 M24.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio64.2667.64172
Slightly volatile
Days Sales Outstanding7901.2 K783
Slightly volatile
Stock Based Compensation To Revenue11.178.475.4891
Slightly volatile
EV To Sales55.9958.93158
Slightly volatile
Payables Turnover0.510.450.463
Pretty Stable
Sales General And Administrative To Revenue17.128.86.3744
Slightly volatile
Research And Ddevelopement To Revenue45.0228.721.6002
Slightly volatile
Capex To Revenue0.220.230.5164
Slightly volatile
Cash Per Share5.976.2997.6434
Slightly volatile
Days Payables Outstanding644848794
Very volatile
Income Quality1.00.850.908
Very volatile
Intangibles To Total Assets0.00190.00240.0023
Pretty Stable
Net Debt To EBITDA0.220.235.3002
Slightly volatile
Current Ratio17.4318.3445.6397
Slightly volatile
Receivables Turnover0.480.30.5254
Slightly volatile
Capex Per Share0.01540.01620.4822
Slightly volatile
Revenue Per Share0.07650.08060.6221
Slightly volatile
Interest Debt Per Share0.370.390.5298
Pretty Stable
Debt To Assets0.0330.05010.022
Slightly volatile
Days Of Payables Outstanding644848794
Very volatile
Ebt Per Ebit1.031.040.9705
Very volatile
Quick Ratio17.4318.3447.2792
Slightly volatile
Net Income Per E B T0.70.790.8669
Slightly volatile
Cash Ratio2.682.8236.2076
Slightly volatile
Days Of Sales Outstanding7901.2 K783
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.161.0525
Slightly volatile
Fixed Asset Turnover0.190.21.9177
Slightly volatile
Debt Ratio0.0330.05010.022
Slightly volatile
Price Sales Ratio64.2667.64172
Slightly volatile
Asset Turnover0.01250.01320.0711
Slightly volatile

Relay Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap503.3 M529.8 M720.4 M
Slightly volatile

Relay Fundamental Market Drivers

Relay Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue8.8 M6.2 M
Total Revenue9 M14 M
Cost Of Revenue6.3 M4.3 M
Stock Based Compensation To Revenue 8.47  11.17 
Sales General And Administrative To Revenue 8.80  17.12 
Research And Ddevelopement To Revenue 28.70  45.02 
Capex To Revenue 0.23  0.22 
Revenue Per Share 0.08  0.08 
Ebit Per Revenue(33.50)(35.17)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY